Prostate Cancer Integrated Polygenic Risk Score™
What is our Integrated PRS (iPRS™) for Prostate Cancer test?
The MyOme Integrated Polygenic Risk Score™ (iPRS™) for Prostate Cancer combines whole-genome insights with clinical factors—such as age, family history, ancestry, and PSA levels—to provide a person’s absolute 10-year and remaining lifetime risk of developing prostate cancer.
This integrated approach is more accurate than traditional clinical risk factors alone, helping enable earlier, more personalized screening and prevention strategies. The test has been validated across ancestrally diverse cohorts (>140,000 individuals) to ensure broad applicability and equity in predictive performance
Comprehensive Prostate Cancer Risk Assessment with iPRS
Broad Eligible Population
About 60% of prostate cancer risk is caused by heritable factors, many of which can be detected as genetic markers by the iPRS test1
Beyond Single-Gene Screening
Up to 95% of individuals do not have a single-gene prostate cancer condition, but may have genetic risk factors detectable by the iPRS test.2
Hidden Risk Detection
Our studies showed 8.6% of men with no family history of prostate cancer were identified as high risk by iPRS, and had ~3X higher prostate cancer incidence compared to the non-risk group3
Clinical risk factor analysis includes:
- Current Age
- Family history of prostate cancer
Who is this test for?
The Prostate Cancer iPRS test is intended for individuals aged 30-75 years* who:
- Do not have a personal history of prostate cancer, and
- Do not have a pathogenic variant in one of the following cancer-associated genes: ATM, BRCA1, BRCA2, CHEK2, HOXB13, MSH2, MLH1, MSH6, PALB2, PMS2, or TP53
By providing a personalized risk estimate, the iPRS test supports informed decisions about screening, prevention, and follow-up, helping patients and providers work together to improve long-term health outcomes
Test Code
PR41034
(Proactive Health Plus)
PR42038
(Proactive Health)
Turnaround Times
From samples received, most results are delivered in 5 to 6 weeks*.
If you've already had MyOme testing performed, follow-up testing or re-requisitions are typically completed in under 2 weeks, often within just a few days.
Acceptable Sample Types
- Blood
- Buccal
- Saliva
Laboratory Accreditation
MyOme is CLIA-certified and CAP-accredited, ensuring the highest standards of quality and accuracy in our testing.
Order a Prostate Cancer iPRS test
We make it easy to order a Prostate Cancer iPRS test to support personalized screening and prevention decisions.
This test can be ordered as part of the MyOme Proactive Health or MyOme Proactive Health Plus offerings, or as a standalone test, depending on your needs. In addition, it can be ordered by itself.
Proactive Health Plus, Prostate Cancer iPRS, Technical One Pager
Proactive Health, Prostate Cancer iPRS, Technical One Pager
Interpreting Prostate Cancer iPRS Results
Implications for Prostate Cancer and Risk Reduction
Clinical guidelines recommend using established risk factors—such as family history, ancestry, age, PSA levels, and digital rectal exam findings—to guide prostate cancer screening and management.
At higher levels of estimated risk, earlier or more frequent screening may be recommended, including periodic PSA testing, imaging (e.g., MRI), or referral to urology for further evaluation. For some individuals, discussions around preventive strategies and monitoring options help reduce the likelihood of late detection and support timely intervention.
Additional diagnostic testing—such as advanced PSA metrics, prostate MRI, or targeted biopsy—may further refine an individual’s risk profile. A prostate cancer iPRS provides an added layer of genetic insight, supporting a more personalized risk management plan tailored to each individual.
Important considerations
The Prostate Cancer iPRS test is a screening tool, not a diagnostic test. It does not detect high-penetrance, single-gene prostate cancer variants. Some individuals at increased risk will not develop prostate cancer, while others with low risk may.
Providers should consider personal and family history when evaluating results and may refer patients for additional genetic testing or counseling as appropriate.
Get more information on how to order a MyOme test and get the process started.
+Thumbnail.jpg&w=1536&q=100)
+Thumbnail.jpg&w=1536&q=100)